Research programme: VEGF receptor inhibitors - Bayer HealthCare Pharmaceuticals

Drug Profile

Research programme: VEGF receptor inhibitors - Bayer HealthCare Pharmaceuticals

Alternative Names: ZK 261991

Latest Information Update: 22 Mar 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 29 Mar 2010 Preclinical development is ongoing in Germany
  • 11 May 2007 Preclinical trials in Solid tumours in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top